Phase 1
Completed N=26
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
Radiculopathy Lumbar
Source: ClinicalTrials.gov NCT05298306 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcomePrimary: The Number of Participants With Adverse Events by Dose (Part A) — 1; 1; 2; 2 participants
Summary
The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Participants With Adverse Events by Dose (Part A) |
1; 1; 2; 2; 0; 0 | — |
| PRIMARY Change in Baseline Pain With Intravenous LAT8881 in Patients With Lumbar Radicular Pain (Part B) |
3.7; 3.1; -0.8; -0.3; -0.8; -0.3 | 0.5196 |
| SECONDARY Maximum Plasma LAT8881 Concentration (Cmax) After Intravenous LAT8881 (Part A) |
12.6; 10.2; 13.8 | — |
| SECONDARY Time to Maximum Plasma LAT8881 Concentration (Tmax) After Intravenous LAT8881 (Part A) |
0.08; 0.08; 0.08 | — |
| SECONDARY Area Under the Concentration Time Curve From Zero to Infinity (AUC0-inf) After Intravenous LAT8881 (Part A) |
NA; NA; NA | — |
| SECONDARY Terminal Elimination Half Life (T1/2), (Part A) |
NA; NA; NA | — |
| SECONDARY Patient General Impression of Change (Part B) |
2; 0; 3; 2; 4; 11 | — |
| SECONDARY The Number of Participants With Adverse Events After Intravenous LAT8881 in Patients With Lumbar Radicular Pain (Part B) |
5; 4; 0; 0; 0; 0 | — |
Eligibility Criteria
Key Inclusion Criteria
For PART A, the following inclusion criteria apply:
- Male or female healthy participants, aged 18-49 years inclusive at screening;
- Body mass index of ≥ 19.0 kg/m2 to ≤ 32.0 kg/m2 at screening;
- Female participants must not be pregnant or breastfeeding
- Male participants with a female partner of childbearing potential must use highly effective contraception for 60 days after the last dose of study treatment
For PART B, the following key inclusion criteria apply:
- Male or female participants with unilateral pain, aged 18 years and above at screening;
- Body mass index of ≥ 19.0 kg/m2 at screening.
- Female participants must not be pregnant or breastfeeding
- Male participants with a female partner of childbearing potential must use highly effective contraception for 60 days after the last dose of study treatment
- Presenting with a history of unilateral pain, radiating into a lower limb, of lancinating, burning, stabbing or electric quality, of duration of >3 months.
- Pain scores (NRS) for average daily leg pain at rest at the relevant nerve root of a mean of ≥4/10 and ≤9/10 for 3 days prior to treatment, with a minimum of >3/10 on any day.
- Demonstration of disc herniation within 6 months by CT or MRI at a segmental level consistent with the clinical features.
- The site of disc herniation must affect L1-2, L2-3, L3-4, L4-5 or L5-S1.
- The patient is willing to keep all analgesic medication and other therapy usage stable or decreased in the week prior to, and a week after, IP administration.
- The patient is in good general health, with the exception of the presenting condition under study
Key Exclusion Criteria
The following key exclusion criteria apply for both PART A and PART B:
- Any condition which might be a risk to participant safety or interfere with study evaluation
- Unwillingness to abstain from alcohol or nicotine products as required
The following additional key exclusion criteria apply to PART B:
- A history of significant pain unrelated to disc herniation that would significantly compromise assessment of leg radicular pain.
- Radiological evidence of foraminal stenosis or of clinically significant spinal stenosis .
- Lumbar back surgery related to the specific disc.
- Injection of an epidural corticosteroid injection within 3 months of screening.
Data sourced from ClinicalTrials.gov (NCT05298306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.